Results 171 to 180 of about 1,271,098 (314)
Growth Factor-Primed WJ-MSC Secretome Enhances Fibroblast Expansion <em>In Vitro</em>
Katia Jarquín-Yáñez +8 more
openalex +2 more sources
We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto +8 more
wiley +1 more source
PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer. [PDF]
Wang Y +9 more
europepmc +1 more source
STRONGLY -ADDITIVE FUNCTIONS AND DISTRIBUTIONAL PROPERTIES OF THE LARGEST PRIME FACTOR
Mohammed Amin Amri +2 more
openalex +1 more source
On sums involving reciprocals of the largest prime factor of an integer II [PDF]
Aleksandar Ivić
openalex +1 more source
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source
Treating RBM20-related cardiomyopathy-Ready for prime time? [PDF]
Kohn J, Lauerer AM, Hegner P, Lebek S.
europepmc +1 more source
Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller +17 more
wiley +1 more source

